Related Experiment Video
Updated: Jan 23, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Clinical implications of mismatch repair deficiency in prostate cancer
Ramy Sedhom1, Emmanuel S Antonarakis1
1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.
Abstract:
Immune checkpoint blockade holds great promise in the treatment of solid tumors but has not yet been approved for use in advanced prostate cancer. This is largely due to the relatively modest response in clinical trials in unselected patients and the lack of available biomarkers to predict clinical benefit. Germline and somatic mismatch repair (MMR) gene deficiencies are more prevalent than previously thought, especially in the metastatic setting, in patients with high-grade Gleason scores and in patients with variant histologies. An early signal suggests that patients with deficiency in MMR may respond well to immunotherapy. Both germline and somatic genetic testing are recommended, yet questions remain on the best modality for testing given lack of standardization and false-negative results in patients with complex genomic structural rearrangements. Expanded panels, such as next generation sequencing may increase the sensitivity without compromising specificity. Future studies are still needed to explore the relationships of hypermutation, tumor mutational burden, tumor-infiltrating lymphocytes and microsatellite instability-H status as predictors of response to immunotherapy. The drivers of variable response is largely unknown, and a more mature understanding of the mechanisms of resistance in deficiencies in MMR tumors may help to more precisely inform use of immunotherapy in prostate cancer.
Insights
Mismatch repair (MMR) gene deficiencies are increasingly recognized in advanced prostate cancer, suggesting potential response to immunotherapy. Further research is needed to optimize genetic testing and identify predictive biomarkers for this treatment.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Immune checkpoint blockade shows promise for solid tumors but lacks approval for advanced prostate cancer due to modest response rates and lack of predictive biomarkers.
- Mismatch repair (MMR) gene deficiencies, both germline and somatic, are more common than previously thought in specific prostate cancer patient groups.
- An emerging signal indicates that patients with MMR deficiencies may benefit from immunotherapy.
Purpose of the Study:
- To review the prevalence and implications of mismatch repair (MMR) gene deficiencies in advanced prostate cancer.
- To discuss the current landscape and challenges of genetic testing for MMR deficiencies.
- To highlight the potential of immunotherapy in MMR-deficient prostate cancer and identify areas for future research.
Main Methods:
- Literature review and synthesis of current research on immune checkpoint inhibitors, MMR deficiencies, and prostate cancer.
- Analysis of the diagnostic challenges and advancements in genetic testing modalities for MMR gene status.
- Exploration of potential biomarkers for immunotherapy response in MMR-deficient tumors.
Main Results:
- Mismatch repair (MMR) gene deficiencies are more prevalent in metastatic prostate cancer, high-grade Gleason scores, and variant histologies.
- Germline and somatic genetic testing are recommended, but standardization and accuracy, especially with complex genomic rearrangements, remain challenges.
- Next-generation sequencing panels may offer improved sensitivity and specificity for detecting MMR deficiencies.
Conclusions:
- Mismatch repair (MMR) deficiency represents a potential predictive biomarker for immunotherapy response in advanced prostate cancer.
- Optimizing genetic testing strategies and further investigating biomarkers like hypermutation and microsatellite instability are crucial.
- Understanding resistance mechanisms in MMR-deficient tumors will refine immunotherapy application in prostate cancer.
Related Concept Videos
01:36Mismatch Repair
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
02:25Overview of DNA Repair
Chemically...
01:54Base Excision Repair
The first step of...
01:08Nucleotide Excision Repair
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...